Welcome to our dedicated page for Biocept news (Ticker: BIOC), a resource for investors and traders seeking the latest updates and insights on Biocept stock.
Biocept, Inc. (symbol: BIOC) is a leading molecular oncology diagnostics company, specializing in the analysis of circulating tumor-associated DNA. The company focuses on both circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) in plasma. Biocept’s mission is to enhance cancer patient outcomes through the advancement of oncology diagnostics.
Utilizing patented and innovative technologies, Biocept delivers clinically relevant prognostic and predictive assessments to physicians, aiding in the treatment course for cancer patients. Their key offering, the Target Selector™ technology, is renowned for its ability to consistently capture extremely rare cells, which may be found in as few as 1 in 50-100 billion blood cells. This technology allows for precise biomarker analysis, assisting in better disease management and treatment decisions.
Beyond direct patient services, Biocept extends its expertise to other laboratory testing providers, academic institutions, research organizations, and biopharmaceutical companies. They play a vital role in clinical trial support, contributing to the development of new cancer therapies.
Biocept’s recent achievements highlight their commitment to innovation and excellence in oncology diagnostics. The company continually strives to expand its technological capabilities and partnerships, ensuring the delivery of high-quality diagnostics solutions to the oncology community.
Biocept, Inc. (Nasdaq: BIOC) will present at the LD Micro Main Event XV on October 26 at 2:30 p.m. PT. The event will be held at the Luxe Sunset Boulevard Hotel in Los Angeles. A live webcast of the presentation will be available on the company's website, where it will also be archived for later viewing. Biocept specializes in molecular diagnostics for cancer treatment, focusing on CNS metastases with its proprietary CNSide™ assay. The company also provides nationwide COVID-19 RT-PCR testing efforts.
Biocept expands the commercial availability of its CNSide assay for metastatic melanoma, designed to enhance treatment decision-making for patients with CNS involvement. This proprietary cerebrospinal fluid assay has already been validated for lung, breast, and other cancers, and is the first CLIA-validated assay for quantitative melanoma cell detection in CSF. With over 60% of Stage IV melanoma patients developing CNS metastasis, CNSide aims to address diagnostic limitations and better inform treatment responses, potentially improving patient outcomes.
Biocept, Inc. (NASDAQ: BIOC) announces a webinar today, October 14, at 1 p.m. ET, showcasing case studies by leading neuro-oncologists on the use of the CNSide assay for managing patients with central nervous system metastasis. Dr. Priya U. Kumthekar from Northwestern University and Dr. Seema A. Nagpal from Stanford University will present their findings. Registration is available here. The webinar will also be archived on Biocept's website.
Biocept, Inc. (NASDAQ: BIOC) is hosting a webinar on October 14 at 1 p.m. ET, featuring case studies on its CNSide assay for assessing central nervous system metastasis in cancer patients. Presenters include neuro-oncologists Dr. Priya U. Kumthekar and Dr. Seema A. Nagpal. The CNSide assay provides enhanced cell capture and digital imaging for better evaluation of tumor cells in cerebrospinal fluid. Biocept aims to lead in neurological tumor diagnostics, with a projected annual market opportunity of $1.2 billion in the U.S. and $2 billion globally.
Biocept, Inc. (NASDAQ: BIOC) announced the granting of inducement stock options for 89,550 shares to 12 new employees on August 31, 2022. The options have an exercise price of $1.03 per share, equal to the closing price on the grant date. These are non-qualified stock options with a ten-year term, vesting over four years, with 25% vesting after one year and the remainder in monthly installments. This action is in compliance with Nasdaq Listing Rule 5635(c)(4) and is part of Biocept's Amended and Restated 2013 Equity Incentive Plan.
Biocept, Inc. (NASDAQ: BIOC) announced on August 17, 2022, it received a notice from Nasdaq regarding non-compliance with listing requirements due to the late filing of its Quarterly Report on Form 10-Q for the period ending June 30, 2022. The delay is attributed to ongoing accounting reviews related to previously reported material weaknesses and issues with COVID-19 testing reimbursements. Biocept has until October 17, 2022, to submit a plan to regain compliance, potentially extending the deadline to February 13, 2023, if accepted.
Biocept, a molecular diagnostics provider, announced a delay in filing its Quarterly Report on Form 10-Q for the quarter ending June 30, 2022. This delay is due to an ongoing review of its financial statements, particularly concerning previously reported material weaknesses and issues related to HRSA funding for COVID-19 testing services. The duration of this delay is currently unknown.
Biocept, Inc. (Nasdaq: BIOC) has appointed RSM US LLP as its new independent registered public accounting firm, effective June 24, 2022, succeeding Mayer Hoffman McCann P.C. (MHM). MHM's departure was not due to any disagreements, as their audit reports on Biocept's financial statements for 2020 and 2021 were unqualified. RSM has been recognized as the fifth-largest accounting firm in the U.S., enhancing Biocept's audit capabilities as it continues to provide molecular diagnostic assays for cancer treatment and monitoring.
Biocept, Inc. (NASDAQ: BIOC) has announced a conference call scheduled for June 7, 2022, at 4:00 p.m. Eastern time. The call aims to discuss a re-focused business strategy and address questions from participants. Pre-registration is available, enabling callers to bypass live operators. Biocept specializes in molecular diagnostic assays for cancer treatment and monitoring, including its CNSide™ assay for detecting metastatic cancer in the central nervous system. The company also offers RT-PCR COVID-19 testing.
Biocept, Inc. (Nasdaq: BIOC) reported a 12% increase in net revenues for Q1 2022, totaling $19.9 million, primarily driven by RT-PCR COVID-19 testing. The company's proprietary CNSide™ assay saw a 219% year-over-year increase in volume. Despite revenue growth, the company experienced a net loss of $2.8 million, compared to a net income of $2.6 million in Q1 2021. Biocept plans to focus on CNSide diagnostics, estimating a $1.2 billion annual market opportunity in the U.S. The company will hold a conference call on June 7, 2022, to discuss its new business strategy.
FAQ
What is the market cap of Biocept (BIOC)?
What does Biocept, Inc. specialize in?
What is Biocept's mission?
What technology is Biocept known for?
Who can benefit from Biocept's services?
What are circulating tumor cells (CTCs)?
How does Biocept’s technology assist physicians?
Does Biocept support clinical trials?
What recent achievements has Biocept made?
Where is Biocept's technology applied?
How does Biocept’s Target Selector™ technology work?
